SIGA Technologies, Inc.  

(Public, NASDAQ:SIGA)   Watch this stock  
Find more results for SIGA
+0.03 (1.34%)
Feb 27 - Close
NASDAQ real-time data - Disclaimer
Currency in USD
Range 2.15 - 2.35
52 week 0.99 - 3.49
Open 2.23
Vol / Avg. 115,694.00/148,328.00
Mkt cap 120.91M
P/E     -
Div/yield     -
EPS -4.69
Shares 53.50M
Beta 1.85
Inst. own 26%

Key stats and ratios

Q3 (Sep '14) 2013
Net profit margin -21836.47% -311.22%
Operating margin -16556.77% -426.07%
EBITD margin - -408.39%
Return on average assets -514.69% -11.46%
Return on average equity - -75.97%
Employees 34 -
CDP Score - -


Suite 1700, 660 Madison Avenue
NEW YORK, NY 10065
United States - Map
+1-212-6729100 (Phone)
+1-212-6973130 (Fax)

Website links

External links

Analyst Estimates - MarketWatch
SEC Filings - EDGAR Online
Major Holders - MSN Money


SIGA Technologies, Inc., is a pharmaceutical company. The Company is focused on specializing in the development and commercialization of solutions for serious unmet medical needs and biothreats. The Company�s lead product is Arestvyr (tecovirimat) also known as ST-246, an orally administered antiviral drug that targets orthopoxviruses. While Arestvyr is not yet licensed as safe or effective by the U.S. Food & Drug Administration, it is a small-molecule drug that is being delivered to the strategic national stockpile under Project BioShield. Arestvyr is an investigational product that is not currently approved by the U.S. Food and Drug Administration (FDA) as a treatment of smallpox or any other indication.

Officers and directors

Eric A. Rose M.D. Chairman of the Board, Chief Executive Officer
Age: 63
Bio & Compensation  - Reuters
Daniel J. Luckshire Chief Financial Officer, Executive Vice President, Secretary
Age: 43
Bio & Compensation  - Reuters
William J. Haynes Executive Vice President, General Counsel
Age: 56
Bio & Compensation  - Reuters
Dennis E. Hruby Ph.D. Chief Scientific Officer, Vice President
Age: 62
Bio & Compensation  - Reuters
James J. Antal CPA Independent Director
Age: 63
Bio & Compensation  - Reuters
Michael Jonathan Bayer Independent Director
Age: 66
Bio & Compensation  - Reuters
Thomas E. Constance Independent Director
Age: 77
Bio & Compensation  - Reuters
Jeffrey B. Kindler Independent Director
Age: 58
Bio & Compensation  - Reuters
Joseph W. Marshall III Independent Director
Age: 61
Bio & Compensation  - Reuters